166 results on '"Banai, Shmuel"'
Search Results
2. TCT-204 Effectiveness of Coronary Sinus Reducer Implantation on Coronary Microvascular Function in Patients With Angina and Nonobstructive Coronary Artery Disease.
- Author
-
Konigstein, Maayan and Banai, Shmuel
- Subjects
- *
CORONARY artery disease , *ANGINA pectoris - Published
- 2023
- Full Text
- View/download PDF
3. HbA1c Levels and Long-Term Mortality in Patients Undergoing Coronary Angiography.
- Author
-
Havakuk, Ofer, Banai, Shmuel, Halkin, amir, Konigstein, Maayan, Ben assa, Eyal, Berliner, Shlomo, Ziv-Baran, Tomer, Elbaz, Meital, Revivo, Miri, Keren, Gad, Finkelstein, ariel, and arbel, Yaron
- Subjects
- *
CORONARY angiography , *BIOMARKERS , *INFLAMMATION , *CARDIOVASCULAR diseases risk factors , *ANEMIA - Abstract
Objectives: Previous studies investigating the prognostic value of HbA1c in patients undergoing coronary angiography reported a mixed pattern of results. Therefore, we aimed to better define the prognostic power of HbA1c among coronary catheterized patients. Methods: Patients undergoing coronary angiography (n = 3,749) were divided into four groups according to HbA1c levels (<5,5-6,6-7 and >7%). Cox regression models assessed long-term mortality after adjusting for multiple covariates. Results: Baseline clinical profiles differed in HbA1c groups, with a higher prevalence of comor-bidities in the groups with higher HbA1c levels. Median follow-up was 1,745 days (interquartile range 1,007-2,171). A J-shaped association curve was observed between HbA1c levels and all-cause mortality rates, with patients in the lowest and highest HbA1c groups suffering from significantly higher mortality rates compared to in-between groups (hazard ratio 1.9, 95% CI 1.32-2.74, p = 0.001, and hazard ratio 1.58,95% CI 1.29-1.95, p < 0.001, for the lowest and highest HbA1c groups, respectively). This association persisted after adjustmentforanemia, nutritional status, renal function, cardiovascular risk factors and inflammatory biomarkers. Conclusions: HbA1c levels <5 or >7% are predictors of all-cause mortality in patients undergoing coronary angiography. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Polymer-free drug-eluting stent in unselected patient population: A single center experience.
- Author
-
Konigstein, Maayan, Banai, Shmuel, Herz, Itzhak, Bazan, Samuel, Revivo, Miri, Halkin, Amir, Keren, Gad, Finkelstein, Ariel, and Arbel, Yaron
- Subjects
- *
DRUG-eluting stents , *MEDICAL polymers , *INFLAMMATION , *DRUG coatings , *SUDDEN death , *FOLLOW-up studies (Medicine) - Abstract
Objective To evaluate the clinical performance of the Cre8™ polymer-free drug-eluting-stent in unselected real-life population. Background Inflammation plays a key role in the multi-factorial process eventually leading to target vessel failure (TVF) after drug-eluting-stent (DES) implantation. The local chronic inflammatory reaction in the vessel wall at the site of stent implantation is, at least in part, attributed to interaction between the polymer coating of DES and vessel wall components. The belief that elimination of the polymer will reduce the occurrence of short and long-term TVF has led to the field of polymer-free DES development. Methods and results In this prospective, open-labeled, single-center, uncontrolled trial we enrolled consecutive patients undergoing PCI to receive the Cre8™ stent. The only exclusion criteria were instent restenosis and target vessel diameter < 2.5 mm. Primary end points were cardiac death and target vessel failure (TVF) at 1-year. Overall, 215 patients were enrolled, in which 318 Cre8 stents were implanted. Study population was characterized by a high prevalence of comorbidities including 38% of diabetics. More than 50% presented with acute coronary syndromes. During 1-year of follow-up there were 1 case of sudden death and 1 case of non-cardiac death, as well as 2 cases of TVF. Conclusion In this small single-center trial of unselected real-life population, the polymer-free Cre8™ DES appears to be effective, as it was associated with very low rates of target-vessel-failure up to 1-year follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial.
- Author
-
Jolicoeur, E. Marc, Banai, Shmuel, Henry, Timothy D., Schwartz, Marc, Doucet, Serge, White, Christopher J., Edelman, Elazer, and Verheye, Stefan
- Subjects
- *
CORONARY heart disease treatment , *RANDOMIZED controlled trials , *BLIND experiment , *DRUG efficacy , *ANGINA pectoris , *DOBUTAMINE - Abstract
Background: A growing population of patients lives with severe coronary artery disease not amenable to coronary revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can improve the symptoms of refractory angina in patients with limited revascularization options. Methods/Design: The COSIRA trial is a phase II double-blind, sham-controlled, randomized parallel trial comparing the percutaneously implanted coronary sinus Reducer (Neovasc Inc, Richmond, BC, Canada) to a sham implantation in 124 patients enrolled in Canada, Belgium, England, Scotland, Sweden and Denmark. All patients need to have stable Canadian Cardiovascular Society (CCS) class III or IV angina despite optimal medical therapy, with evidence of reversible ischemia related to disease in the left coronary artery, and a left ventricular ejection fraction >25%. Participants experiencing an improvement in their angina =2 CCS classes six months after the randomization will meet the primary efficacy endpoint. The secondary objective of this trial is to test whether coronary sinus Reducer implantation will improve left ventricular ischemia, as measured by the improvement in dobutamine echocardiogram wall motion score index and in time to 1 mm ST-segment depression from baseline to six-month post-implantation. Discussion: Based on previous observations, the COSIRA is expected to provide a significant positive result or an informative null result upon which rational development decisions can be based. Patient safety is a central concern and extensive monitoring should allow an appropriate investigation of the safety related to the coronary sinus Reducer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. The development of anemia of inflammation during acute myocardial infarction
- Author
-
Steinvil, Arie, Banai, Shmuel, Leshem-Rubinow, Eran, Rogowski, Ori, Halkin, Amir, Keren, Gad, Finkelstein, Ariel, Chundadze, Tamar, Berliner, Shlomo, and Arbel, Yaron
- Subjects
- *
MYOCARDIAL infarction , *ANEMIA , *INFLAMMATION , *ANGIOGRAPHY , *CROSS-sectional method , *CARDIAC catheterization , *ANALYSIS of variance , *MEDICAL statistics - Abstract
Abstract: Background: Anemia is associated with an unfavorable outcome in acute myocardial infarction (AMI). An acute phase response could contribute to the development of anemia in AMI patients. Methods: We have performed a cross-sectional analysis on prospectively collected data at a tertiary hospital catheterization laboratory. Multi-adjusted linear regression models were fitted for hemoglobin as the dependent variable. ANOVA tests were used to determine interactions between time cutoffs of the respective hemoglobin and the concentrations of two inflammatory proteins, namely C-reactive protein and fibrinogen. Anemia indices were analyzed in a subgroup of 138 male AMI patients for whom frozen serum samples were available. Results: Enrolled were 1017 patients (340 with unstable angina pectoris [UAP] and 677 with AMI). Correlates of hemoglobin in the AMI group included age, male gender, the inflammatory proteins, as well as time from symptom onset to angiography (r 2 =0.47; p <0.001). A significant decrease in the concentration of hemoglobin with a parallel increase in the inflammatory proteins was observed between the time cutoff from symptom onset to angiography only in the AMI group for males and females, respectively. A pattern suggestive of anemia of inflammation including higher ferritin, lower transferring, lower transferrin saturation, and lower serum iron concentrations has been observed in anemic AMI patients ( all p <0.05). Conclusions: Inflammation-sensitive proteins are associated with lower hemoglobin concentrations in AMI patients. We therefore suggest the possibility that at least part of the hemoglobin drop in AMI prior to angiography is related to the anemia of inflammation. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
7. Erythrocyte aggregation as a cause of slow flow in patients of acute coronary syndromes
- Author
-
Arbel, Yaron, Banai, Shmuel, Benhorin, Jessia, Finkelstein, Ariel, Herz, Itzhak, Halkin, Amir, Keren, Gad, Yedgar, Saul, Barashtein, Gershon, and Berliner, Shlomo
- Subjects
- *
ERYTHROCYTES , *CORONARY disease , *MYOCARDIUM , *CHEST pain , *CARDIAC catheterization , *ANGIOGRAPHY , *FIBRINOGEN , *THROMBOLYTIC therapy - Abstract
Abstract: Background: There are multiple lines of evidence to suggest the role of erythrocyte aggregation (EA) in microcirculatory dysfunction during conditions of very slow flow. Such conditions might develop in the myocardium of patients with acute coronary syndromes (ACS). Methods: EA as a function of shear stress was evaluated by using a cell flow properties analyzer (CFA) in a cohort of 91 ACS patients and in 36 patients with non specific chest pain or heart failure at the time of cardiac catheterization. Results: The ACS group included 34 patients with acute myocardial infarction and 57 patients with unstable angina. In addition, we examined 36 patients who underwent angiography for non specific chest pain or heart failure. A significant (r=0.44, p<0.0005) correlation was found between the concentration of fibrinogen and the average aggregate size (AAS) only when using conditions of very slow flow and applying relatively low (0.15dyn/cm2) shear stress in the ACS group. This correlation decreased and became insignificant when applying shear stress forces of 1dyn/cm2 and more. This correlation was nonsignificant for all the 5 shear stress forces (between 0.15 and 4dyn/cm2) in the samples obtained from the non-ACS group. Conclusion: Erythrocytes that are suspended in autologous plasma obtained from patients with ACS tend to aggregate in conditions of very slow flow. These findings might be detrimental in terms of microcirculatory flow in ACS patients and might open new therapeutic options such as the use of low dose thrombolysis following PCI. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. Diagnostic Yield of Extensive Infectious Panel Testing in Acute Pericarditis.
- Author
-
Abu Fanne, Rami, Banai, Shmuel, Chorin, Udi, Rogowski, Ori, Keren, Gad, and Roth, Arie
- Subjects
- *
PERICARDITIS , *THROAT diseases , *CORONARY arteries , *C-reactive protein , *ECHOCARDIOGRAPHY - Abstract
Objective: In an attempt to reconsider our local strategy, we evaluated patients with viral/idiopathic pericarditis in order to assess the diagnostic yield of our standard infectious panel, the characteristics of myocardial involvement, the utility of investigating myocardial involvement and the incidence of coronary evaluation tests. Methods: Seventy-six consecutive cases of idiopathic/viral acute pericarditis treated between March 2005 and March 2008 were retrospectively enrolled. Telephonic questionnaires were answered by all. Results: Myopericarditis was recorded in 45/71 (63.4%) consecutive patients. Sore throat on presentation (38 vs. 12%; p = 0.027) was the only symptom independently associated with myopericarditis. The following clinical features were significantly correlated with pericarditis rather than myopericarditis: age (42 ± 16 vs. 32 ± 12; p = 0.008), C-reactive protein (131 ± 75 vs. 78 ± 58; p = 0.009) and lower CPK and troponin levels (mean 96 vs. mean 489; p < 0.001 and mean 0 vs. mean 10; p < 0.001, respectively). The infectious panel revealed 6 positive results. After an average 3 years' fol- low-up, recurrence was documented in 5 patients (7%). No patient initially regarded idiopathic developed systemic disease during follow-up. Conclusions: Among patients presenting with presumed idiopathic/viral pericarditis, myopericarditis is relatively common and has a benign evolution. Extensive serological investigation with a broad infectious panel proved to be diagnostically and therapeutically futile in our area. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Coronary Sinus Reducer Stent for the Treatment of Chronic Refractory Angina Pectoris: A Prospective, Open-Label, Multicenter, Safety Feasibility First-in-Man Study
- Author
-
Banai, Shmuel, Ben Muvhar, Shmuel, Parikh, Keyur H., Medina, Aharon, Sievert, Horst, Seth, Ashok, Tsehori, Jonathan, Paz, Yoav, Sheinfeld, Ami, and Keren, Gad
- Subjects
- *
CORONARY arteries , *CORONARY artery bypass , *MYOCARDIAL revascularization , *DIAGNOSTIC ultrasonic imaging - Abstract
Objectives: This study sought to evaluate the safety of the Coronary Sinus Reducer (Neovasc Medical, Inc., Or Yehuda, Israel) as a potential alternate therapy for patients with refractory angina who are not candidates for conventional revascularization procedures. Background: Increased coronary sinus (CS) pressure can reduce myocardial ischemia by redistribution of blood from nonischemic to ischemic territories. The Coronary Sinus Reducer is a percutaneous implantable device designed to establish CS narrowing and to elevate CS pressure. In preclinical experiments, implantation of the Reducer was safe and was associated with improved ischemic parameters. In the present study, the safety and feasibility of the Coronary Sinus Reducer was evaluated in patients with refractory angina who were not candidates for revascularization. Methods: Fifteen coronary artery disease patients with severe angina and reversible ischemia were electively treated with the Reducer. Clinical evaluation, dobutamine echocardiography, thallium single-photon emission computed tomography, and administration of an angina questionnaire were performed before and 6 months after implantation. Cardiac computed tomography was performed 2 days and 6 months after implantation. Results: All procedures were completed successfully. No procedure-related adverse events occurred during the periprocedural and the follow-up periods. Angina score improved in 12 of 14 patients. Average Canadian Cardiovascular Society score was 3.07 at baseline and 1.64 at follow-up (n = 14, p < 0.0001). Stress-induced ST-segment depression was reduced in 6 of 9 patients and was eliminated in 2 of these 6 (p = 0.047). The extent and severity of myocardial ischemia by dobutamine echocardiography and by thallium single-photon emission computed tomography was reduced (p = 0.004 [n = 13] and p = 0.042 [n = 10], respectively). Conclusions: Implantation of the Coronary Sinus Reducer is feasible and safe. These findings, along with the clinical improvement observed, support further evaluation of the Reducer as an alternative treatment for patients with chronic refractory angina who are not candidates for coronary revascularization. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
10. Erratum to ‘Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries’ [Biomaterials 26 (2005) 451–461]
- Author
-
Banai, Shmuel, Chorny, Michael, David Gertz, S., Fishbein, Ilia, Gao, Jianchuan, Perez, Louise, Lazarovich, Galila, Gazit, Aviv, Levitzki, Alexander, and Golomb, Gershon
- Published
- 2005
- Full Text
- View/download PDF
11. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries
- Author
-
Banai, Shmuel, Chorny, Michael, Gertz, S. David, Fishbein, Ilia, Gao, Jianchuan, Perez, Louise, Lazarovichi, Galila, Gazit, Aviv, Levitzki, Alexander, and Golomb, Gershon
- Subjects
- *
DRUG delivery systems , *CORONARY restenosis , *HYPERPLASIA , *CELLULAR pathology - Abstract
Local delivery of antiproliferative drugs encapsulated in biodegradable nanoparticles (NP) has shown promise as an experimental strategy for preventing restenosis development. A novel PDGFRβ-specific tyrphostin, AGL-2043, was formulated in polylactide-based nanoparticles and was administered intraluminally to the wall of balloon-injured rat carotid and stented pig coronary arteries. The disposition and elimination kinetics within the vessel wall, as well as the antirestenotic potential of the novel drug and delivery system, were evaluated. The efficacy and the local drug elimination kinetics were affected by the size of the NP and the drug-carrier binding mode. Despite similar arterial drug levels 90 min after delivery in rats, small NP were more efficacious in comparison to large NP (90 and 160 nm, respectively). AGL-2043 selectively inhibited vascular SMC in a dose-dependent manner. The antiproliferative effect of nanoencapsulated tyrphostin was considerably higher than that of surface-adsorbed drug. In the pig model, intramural delivery of AGL-2043 resulted in reduced in-stent neointima formation in the coronary arteries over control despite similar degrees of wall injury. The results of this study suggest that locally delivered tyrphostin AGL-2043 formulated in biodegradable NP may be applicable for antirestenotic therapy independent of stent design or type of injury. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
12. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries
- Author
-
Banai, Shmuel, Gertz, S. David, Gavish, Lilach, Chorny, Michael, Perez, Louise S., Lazarovichi, Galila, Ianculuvich, Mickey, Hoffmann, Michael, Orlowski, Michael, Golomb, Gershon, and Levitzki, Alexander
- Subjects
- *
CORONARY arteries , *ANGIOPLASTY , *CORONARY restenosis , *SURGICAL stents - Abstract
Objective: Tyrphostin AGL-2043 is a potent tricyclic quinoxaline inhibitor of PDGF β-receptor tyrosine kinase (PTK), Kit, and Flt3. We have shown previously that selective inhibition of PDGF β-receptor PTK by tyrphostins markedly reduces SMC proliferation and migration in vitro, reduces neointima formation in balloon-injured porcine femoral arteries, and reduces neointimal stenosis in stented porcine coronary arteries when administered intramurally within biodegradable nanoparticles. The present study was designed to determine the effect of AGL-2043 delivered from a stent-based, biodegradable polymeric coating on neointima formation in the porcine coronary artery model. Methods and Results: Stents coated with biodegradable, polylactic/glycolic acid (PLGA) polymer, with (n=13) or without (n=11) 180 mcg AGL-2043 were implanted into the proximal LAD of 24 Sinclair mini-pigs (34±4 kg) to achieve a 1.1:1 stent/artery diameter ratio. The delivery of drug from stent to tissue was confirmed by high-performance liquid chromatography. After 28 days, histomorphometric analysis showed that in-stent stenosis in animals treated with AGL-2043 was reduced by 50% (51±21% versus 26±10%, p=0.001), the absolute neointimal area was reduced by 44% (2.38±1.04 versus 1.31±0.43 mm2, p=0.004), and the absolute luminal area was increased by 57% (2.19±1.09 versus 3.39±0.59 mm2, p=0.003). There were no significant differences between control and AGL-2043 in injury score (1.24±0.11 vs. 1.15±0.12, p=0.07) or inflammation score (1.19±0.35 vs. 1.07±0.33, p=0.41). Moreover, the difference in % in-stent stenosis between control and treated animals remained highly significant even after normalizing the % stenosis to the degree of injury (p=0.0008) or to the inflammation score (p=0.001). Mortality for this study was zero. Tissue concentration in segments 1 cm proximal and distal to the stents, were negligible or zero at 1 h, 24 h, and 4 weeks after stent implantation. Conclusion: Stent-based delivery of tyrphostin AGL-2043 from a biodegradable polymeric coating reduces in-stent neointimal hyperplasia in porcine coronary arteries by 50% after 28 days and preserves lumen area. Long-term studies should be the next step in testing applicability to the human interventional setting. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
13. Prospective study of bacteremia aftercardiac catheterization
- Author
-
Banai, Shmuel, Selitser, Vera, Keren, Andre, Benhorin, Jesaia, Ben Shitrit, Orly, Yalon, Shaul, and Halperin, Efraim
- Subjects
- *
CARDIAC catheterization , *CARDIAC surgery , *HEART diseases , *BACTEREMIA - Abstract
Nine hundred sixty consecutive cardiac catheterization procedures were studied prospectively for the presence of periprocedural bacteremia. Overall, among 960 procedures, only 4 were associated with clinically significant bacteremia. All 4 were related to the intravenous line and none to the cardiac procedure itself. Clinically nonsignificant bacteremias were correlated with procedural duration, multiple skin punctures, use of multiple balloons, and obesity. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
14. Traditional Cardiovascular Risk Factors and Coronary Microvascular Dysfunction in Women and Men: A Single-Center Study.
- Author
-
Zornitzki, Lior, Shetrit, Aviel, Freund, Ophir, Frydman, Shir, Banai, Ariel, Amar Shamir, Reut, Ben-Shoshan, Jeremy, Arbel, Yaron, Banai, Shmuel, and Konigstein, Maayan
- Subjects
- *
MYOCARDIAL ischemia , *MICROCIRCULATION disorders , *BLOOD flow measurement , *CORONARY disease , *CARDIOVASCULAR diseases risk factors - Abstract
Introduction: Coronary microvascular dysfunction (CMD) is common in patients with and without obstructive epicardial coronary artery disease (CAD). Risk factors for the development of CMD have not been fully elucidated, and data regarding sex-associated differences in traditional cardiovascular risk factors for obstructive CAD in patients with CMD are lacking. Methods: In this single-center, prospective registry, we enrolled patients with nonobstructive CAD undergoing clinically indicated invasive assessment of coronary microvascular function between November 2019 and March 2023. Associations between coronary microvascular dysfunction, traditional cardiovascular risk factors, and sex were assessed using univariate and multivariate regression models. Results: Overall, 245 patients with nonobstructive CAD were included in the analysis (62.9% female; median age 68 (interquartile range: 59, 75). Microvascular dysfunction was diagnosed in 141 patients (57.5%). The prevalence of microvascular dysfunction was similar in women and men (59.0% vs. 57.0%; p = 0.77). No association was found between traditional risk factors for coronary atherosclerosis and CMD regardless of whether CMD was structural or functional. In women, but not in men, older age and the presence of previous ischemic heart disease were associated with lower coronary flow reserve (β = −0.29; p < 0.01 and β = −0.15; p = 0.05, respectively) and lower resistive reserve ratio (β = −0.28; p < 0.01 and β = −0.17; p = 0.04, respectively). Conclusion: For the entire population, no association was found between coronary microvascular dysfunction and traditional risk factors for coronary atherosclerosis. In women only, older age and previous ischemic heart disease were associated with coronary microvascular dysfunction. Larger studies are needed to elucidate risk factors for CMD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model.
- Author
-
Unger, Ellis F. and Banai, Shmuel
- Subjects
- *
FIBROBLAST growth factors , *COLLATERAL circulation , *ISCHEMIA , *CELL proliferation - Abstract
Determines the effects of exogenously administered basic fibroblast growth factor on collateral blood flow to ischemic myocardium. Systemic hemodynamic measurements; Biochemical and hematologic data; Histological examination of noncardiac organs; Regional myocardial blood flow; Vascular density; Infarct area; Cellular proliferation.
- Published
- 1994
16. NARROWING OF THE CORONARY SINUS FOR THE TREATMENT OF REFRACTORY ANGINA PECTORIS A MULTICENTER PROSPECTIVE OBSERVATIONAL OPEN LABEL CLINICAL TRIAL (THE REDUCER I TRIAL): ANALYSIS OF THE FIRST 207 PATIENTS.
- Author
-
Banai, Shmuel, Konigstein, Maayan, Agostoni, Pierfrancesco, Giannini, Francesco, Hill, Jonathan M., and Verheye, Stefan
- Subjects
- *
ANGINA pectoris , *CLINICAL trials , *CORONARY disease - Published
- 2020
- Full Text
- View/download PDF
17. Tissue factor as a therapeutic target in coronary syndromes.
- Author
-
Banai, Shmuel, Gertz, S. David, Banai, S, and Gertz, S D
- Subjects
- *
GLYCOPROTEINS , *BLOOD coagulation factors , *HEMOSTASIS , *ATHEROEMBOLISM , *CORONARY heart disease complications , *RECOMBINANT proteins , *LIPOPROTEINS , *ANGINA pectoris , *ANIMALS , *ANTICOAGULANTS , *BLOOD vessels , *CORONARY disease , *MYOCARDIAL revascularization , *THROMBOPLASTIN , *THROMBOSIS , *TRANSLUMINAL angioplasty , *DISEASE relapse , *CHEMICAL inhibitors , *THERAPEUTICS - Abstract
Focuses on the tissue factor (TF), a low molecular weight membrane-bound glycoprotein and a major regulator of coagulation and determinant of thrombin generation in normal hemostasis and atherothrombotic disease. First step in the coagulation process; Presence of TF on cells; Proteolytic activity of TF.
- Published
- 2001
- Full Text
- View/download PDF
18. Glycoprotein IIb/IIIa receptor antagonists in acute myocardial infarction and primary coronary stenting: Not always effective.
- Author
-
Banai, Shmuel, Medina, Aharon, and Keren, Andre
- Subjects
- *
CHEST pain treatment , *GLYCOPROTEINS , *DRUG efficacy - Abstract
Glycoprotein IIb/IIIa antagonists have been shown to be effective in reducing thrombotic complications prior to high-risk coronary interventions. Some studies have reported improved coronary flow after abciximab in slow or no-reflow phenomenon. We report a case in which abciximab did not clear the thrombotic occlusion or restore artery flow. Further studies are needed into the refractory no-flow phenomenon. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
19. A device to narrow the coronary sinus for angina.
- Author
-
Banai, Shmuel, Verheye, Stefan, and Jolicoeur, E Marc
- Published
- 2015
- Full Text
- View/download PDF
20. A Device to Narrow the Coronary Sinus for Angina.
- Author
-
Banai, Shmuel, Verheye, Stefan, and Marcjolicœur, E.
- Subjects
- *
ANGINA pectoris , *CORONARY disease , *MEDICAL equipment - Abstract
A response from the authors of the article "Efficacy of a Device to Narrow the Coronary Sinus in Refractory Angina" in the February 5, 2015 issue is presented.
- Published
- 2015
- Full Text
- View/download PDF
21. Clinical impact of post procedural mitral regurgitation after transcatheter aortic valve replacement.
- Author
-
Ben-Assa, Eyal, Biner, Simon, Banai, Shmuel, Arbel, Yaron, Laufer-Perl, Michal, Kramarz, Judith, Elmariah, Sammy, Inglessis, Ignacio, Keren, Gad, Finkelstein, Ariel, and Topilsky, Yan
- Subjects
- *
HEART valve prosthesis implantation , *MITRAL valve insufficiency , *PROPENSITY score matching , *VENTRICULAR remodeling , *AORTIC valve transplantation - Abstract
While the impact of mitral regurgitation (MR) prior to transcatheter aortic valve replacement (TAVR) has been intensively studied, the implications of post-procedural MR on outcome are unknown. We investigated the clinical and physiological impact of significant MR after TAVR. Clinical and echocardiographic data of 486 patients who underwent TAVR between March 2009 and December 2014 were evaluated. Clinical endpoints included overall mortality and combined endpoint of mortality, heart failure re-hospitalization and new atrial fibrillation. Echocardiographic parameters were analyzed at baseline, 30-day and 6-month after TAVR. MR severity improved in 25%, worsened in 19% and did not change in 56% of patients 30-days post TAVR (p = 0.3). Post TAVR MR grade ≥ moderate was present in 16.1%. Predictive accuracy of post TAVR MR was low (AUC = 0.63). Median follow-up was 4.3 years (interquartile range, 2.5 to 6.1). Post TAVR MR grade ≥ moderate was associated with increased mortality and combined cardiac events (p = 0.013 and p < 0.001) even when adjusted for all clinical and echo parameters and when analyzed with propensity score matching. In patients with MR ≥ moderate, LV filling pressure and RV hemodynamics worsened 6 months post TAVR, while improving in patients with less significant post procedural MR. Post procedural, but not pre-procedural MR grade ≥ moderate was independently associated with mortality and adverse cardiac events after TAVR. Significant MR post TAVR resulted in adverse LV and RV remodeling and poor hemodynamic. Our study strengthens the rational for initiating early treatment to reduce post TAVR MR. • Mitral regurgitation (MR) after transcatheter aortic valve replacement (TAVR) is poorly predicted by pre-procedural MR. • Post TAVR, but not pre-procedural ≥ moderate MR was independently associated with mortality and adverse cardiac events. • Significant MR post TAVR resulted in adverse left and right ventricular remodeling and poor hemodynamic. • Our study supports initiation of early treatment to reduce post TAVR MR before ventricular dysfunction or symptoms occur. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Tiara: A Novel Catheter-Based Mitral Valve Bioprosthesis: Initial Experiments and Short-Term Pre-Clinical Results
- Author
-
Banai, Shmuel, Jolicoeur, E. Marc, Schwartz, Marc, Garceau, Patrick, Biner, Simon, Tanguay, Jean-Francois, Cartier, Raymond, Verheye, Stefan, White, Christopher J., and Edelman, Elazer
- Published
- 2012
- Full Text
- View/download PDF
23. The Mechanism of Effort Intolerance in Patients with Peripheral Arterial Disease: A Combined Stress Echocardiography and Cardiopulmonary Exercise Test.
- Author
-
Ghantous, Eihab, Shetrit, Aviel, Erez, Yonatan, Noam, Natalie, Zamanzadeh, Ryan S., Zahler, David, Granot, Yoav, Levi, Erez, Perl, Michal Laufer, Banai, Shmuel, Topilsky, Yan, and Havakuk, Ofer
- Subjects
- *
STRESS echocardiography , *EXERCISE tests , *PERIPHERAL vascular diseases , *ANAEROBIC threshold , *CORONARY artery disease - Abstract
Aim: We used a combined stress echocardiography and cardiopulmonary exercise test (CPET) to explore effort intolerance in peripheral arterial disease (PAD) patients. Methods: Twenty-three patients who had both PAD and coronary artery disease (CAD) were compared with twenty-four sex- and age-matched CAD patients and fifteen normal controls using a symptom-limited ramp bicycle CPET on a tilting dedicated ergometer. Echocardiographic images were obtained concurrently with gas exchange measurements along predefined stages of exercise. Oxygen extraction was calculated using the Fick equation at each activity level. Results: Along the stages of exercise (unloaded; anaerobic threshold; peak), in PAD + CAD patients compared with CAD or controls, diastolic function worsened (p = 0.051 and p = 0.013, respectively), and oxygen consumption (p < 0.001 and p < 0.001, respectively) and oxygen pulse (p = 0.0024 and p = 0.0027, respectively) were reduced. Notably, oxygen pulse was blunted due to an insufficient increase in both stroke volume (p = 0.025 and p = 0.028, respectively) and peripheral oxygen extraction (p = 0.031 and p = 0.038, respectively). Chronotropic incompetence was more prevalent in PAD patients and persisted after correction for beta-blocker use (62% vs. 42% and 11%, respectively). Conclusions: In PAD patients, exercise limitation is associated with diastolic dysfunction, chronotropic incompetence and peripheral factors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. The Dynamic Nature of Self-Assessed Health (SAH) as a Function of Negative and Positive Affects among Cardiac Patients.
- Author
-
Peleg, Shira, Drori, Erga, Banai, Shmuel, Finkelstein, Ariel, and Shiloh, Shoshana
- Subjects
- *
HEALTH outcome assessment , *EVALUATION of medical care , *CARDIAC patients , *AFFECT (Psychology) , *EMOTIONS , *ANGIOPLASTY - Abstract
Background Self-assessed health (SAH) predicts health outcomes above and beyond medical variables. One of the explanations for this robust finding is the sensitivity of SAH to changes in multiple aspects of health, including emotional factors. We assessed the dynamic nature of SAH by longitudinally examining the associations between initial and change levels of SAH and positive affect (PA) and negative affect (NA). Methods Participants were 138 cardiac patients undergoing coronary angioplasty. Self-report questionnaires measured SAH, PA, and NA, one day and one month after catheterisation. Results Means of SAH and NA did not change between measurement points, but PA decreased. Cross-lagged analysis indicated that the best model for representing the data included a path from affect at hospitalisation to SAH one month later; that is, lower NA (but not PA) at hospitalisation predicted higher SAH a month later. A latent change model analysis also revealed that NA (but not PA) at hospitalisation predicted changes in SAH (but SAH did not predict changes in negative or positive affect); and that increases in positive affect and decreases in negative affect were linked to increases in SAH. Conclusions These findings highlight the importance of NA as an indicator of SAH and SAH change, and provide further insights into the dynamics of SAH in cardiac patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. HBA1C LEVELS ARE ASSOCIATED WITH LONG TERM MORTALITY RATES IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY.
- Author
-
Havakuk, Ofer, Banai, Shmuel, Halkin, Amir, Berliner, Shlomo, Herz, Itzhak, Revivo, Miri, Konigstein, Maayan, Assa, Eyal Ben, Keren, Gad, Finkelstein, Ariel, and Arbel, Yaron
- Published
- 2014
- Full Text
- View/download PDF
26. Clustering of clinical and echocardiographic phenotypes of covid-19 patients.
- Author
-
Shpigelman, Eran, Hochstadt, Aviram, Coster, Dan, Merdler, Ilan, Ghantous, Eihab, Szekely, Yishay, Lichter, Yael, Taieb, Philippe, Banai, Ariel, Sapir, Orly, Granot, Yoav, Lupu, Lior, Borohovitz, Ariel, Sadon, Sapir, Banai, Shmuel, Rubinshtein, Ronen, Topilsky, Yan, and Shamir, Ron
- Subjects
- *
COVID-19 , *ECHOCARDIOGRAPHY - Abstract
We sought to divide COVID-19 patients into distinct phenotypical subgroups using echocardiography and clinical markers to elucidate the pathogenesis of the disease and its heterogeneous cardiac involvement. A total of 506 consecutive patients hospitalized with COVID-19 infection underwent complete evaluation, including echocardiography, at admission. A k-prototypes algorithm applied to patients' clinical and imaging data at admission partitioned the patients into four phenotypical clusters: Clusters 0 and 1 were younger and healthier, 2 and 3 were older with worse cardiac indexes, and clusters 1 and 3 had a stronger inflammatory response. The clusters manifested very distinct survival patterns (C-index for the Cox proportional hazard model 0.77), with survival best for cluster 0, intermediate for 1–2 and worst for 3. Interestingly, cluster 1 showed a harsher disease course than cluster 2 but with similar survival. Clusters obtained with echocardiography were more predictive of mortality than clusters obtained without echocardiography. Additionally, several echocardiography variables (E′ lat, E′ sept, E/e average) showed high discriminative power among the clusters. The results suggested that older infected males have a higher chance to deteriorate than older infected females. In conclusion, COVID-19 manifests differently for distinctive clusters of patients. These clusters reflect different disease manifestations and prognoses. Although including echocardiography improved the predictive power, its marginal contribution over clustering using clinical parameters only does not justify the burden of echocardiography data collection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial.
- Author
-
Jolicoeur, E Marc, Banai, Shmuel, Henry, Timothy D, Schwartz, Marc, Doucet, Serge, White, Christopher J, Edelman, Elazer, Verheye, Stefan, and Jolicœur, E Marc
- Abstract
Background: A growing population of patients lives with severe coronary artery disease not amenable to coronary revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can improve the symptoms of refractory angina in patients with limited revascularization options.Methods/design: The COSIRA trial is a phase II double-blind, sham-controlled, randomized parallel trial comparing the percutaneously implanted coronary sinus Reducer (Neovasc Inc, Richmond, BC, Canada) to a sham implantation in 124 patients enrolled in Canada, Belgium, England, Scotland, Sweden and Denmark. All patients need to have stable Canadian Cardiovascular Society (CCS) class III or IV angina despite optimal medical therapy, with evidence of reversible ischemia related to disease in the left coronary artery, and a left ventricular ejection fraction >25%. Participants experiencing an improvement in their angina ≥2 CCS classes six months after the randomization will meet the primary efficacy endpoint. The secondary objective of this trial is to test whether coronary sinus Reducer implantation will improve left ventricular ischemia, as measured by the improvement in dobutamine echocardiogram wall motion score index and in time to 1 mm ST-segment depression from baseline to six-month post-implantation.Discussion: Based on previous observations, the COSIRA is expected to provide a significant positive result or an informative null result upon which rational development decisions can be based. Patient safety is a central concern and extensive monitoring should allow an appropriate investigation of the safety related to the coronary sinus Reducer.Trial Registration: ClinicalTrials.gov identifier - NCT01205893. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
28. TCT-384 The Coronary Sinus Reducer – a Device Based Therapy for Refractory Angina; Interim Safety Results of the ongoing COSIRA clinical Trial and efficacy results of the CS Reducer Registry
- Author
-
Banai, Shmuel, Jolicoeur, Marc, Tanguay, Jean-François, Edelman, Elazer, and Verheye, Stefan
- Published
- 2012
- Full Text
- View/download PDF
29. TCT-107 TIARA - A Novel Catheter-Based Mitral Valve Bio-Prosthesis Short Term Pre-Clinical Results
- Author
-
Banai, Shmuel, Jolicoeur, Marc, Tanguay, Jean-François, Verheye, Stefan, White, Christopher, and Edelman, Elazer
- Published
- 2012
- Full Text
- View/download PDF
30. Response to the letter: How to manage coronary slow flow following PCI?
- Author
-
Arbel, Yaron and Banai, Shmuel
- Published
- 2012
- Full Text
- View/download PDF
31. LONG-TERM FOLLOW-UP TO EVALUATE THE SAFETY OF THE NEOVASC REDUCER A DEVICE-BASED THERAPY FOR CHRONIC REFRACTORY ANGINA
- Author
-
Banai, Shmuel, Schwartz, Marc, Sievert, Horst, Seth, Ashok, Keren, Gad, and Parikh, Keyur H.
- Published
- 2010
- Full Text
- View/download PDF
32. The Straight Wire Sign: Recognizing guidwire exit during percutaneous coronary intervention for chronic total occlusion
- Author
-
Mosseri, Morris, Banai, Shmuel, Jabara, Refat, and Rott, David
- Subjects
- *
HEART diseases , *THERAPEUTICS , *CARDIOVASCULAR diseases , *CARDIAC surgery , *CARDIAC catheterization - Abstract
Abstract: Coronary perforation during PCI may be life threatening. Use of stiff wires during instrumentation of totally occluded arteries is a contributing factor. The “Straight Wire” sign presented here was realized from a case of coronary perforation encountered at our cath lab. The identification of this sign in another patient prompted immediate response and avoided further complications. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
33. Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections.
- Author
-
Topaz, Moris, Chorin, Ehud, Schwartz, Arie Lorin, Hochstadt, Aviram, Shotan, Avraham, Ashkenazi, Itamar, Kazatsker, Mark, Carmel, Narin-Nard, Topaz, Guy, Oron, Yoram, Margolis, Gilad, Nof, Eyal, Beinart, Roy, Glikson, Michael, Mazo, Anna, Milman, Anat, Dekel, Michal, Banai, Shmuel, Rosso, Raphael, and Viskin, Sami
- Subjects
- *
ELECTRONIC equipment , *ARTIFICIAL implants , *DENTAL extraction , *ANTIBIOTICS , *INFECTION , *DEFIBRILLATORS - Abstract
Present guidelines endorse complete removal of cardiovascular implantable electronic devices (pacemakers/defibrillators), including extraction of all intracardiac electrodes, not only for systemic infections, but also for localized pocket infections. The authors evaluated the efficacy of delivering continuous, in situ–targeted, ultrahigh concentration of antibiotics (CITA) into the infected subcutaneous device pocket, obviating the need for device/lead extraction. The CITA group consisted of 80 patients with pocket infection who were treated with CITA during 2007-2021. Of them, 9 patients declined lead extraction because of prohibitive operative risk, and 6 patients had questionable indications for extraction. The remaining 65 patients with pocket infection, who were eligible for extraction, but opted for CITA treatment, were compared with 81 patients with pocket infection and similar characteristics who underwent device/lead extraction as primary therapy. A total of 80 patients with pocket infection were treated with CITA during 2007-2021. CITA was curative in 85% (n = 68 of 80) of patients, who remained free of infection (median follow-up 3 years [IQR: 1.0-6.8 years]). In the case-control study of CITA vs device/lead extraction, cure rates were higher after device/lead extraction than after CITA (96.2% [n = 78 of 81] vs 84.6% [n = 55 of 65]; P = 0.027). However, rates of serious complications were also higher after extraction (n = 12 [14.8%] vs n = 1 [1.5%]; P = 0.005). All-cause 1-month and 1-year mortality were similar for CITA and device/lead extraction (0.0% vs 3.7%; P = 0.25 and 12.3% vs 13.6%; P = 1.00, respectively). Extraction was avoided in 90.8% (n = 59 of 65) of extraction-eligible patients treated with CITA. CITA is a safe and effective alternative for patients with pocket infection who are unsuitable or unwilling to undergo extraction. (Salvage of Infected Cardiovascular Implantable Electronic Devices [CIED] by Localized High-Dose Antibiotics; NCT01770067) [Display omitted] [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. The added predictive role of echocardiography in patients with mild or moderate Coronavirus Disease 2019.
- Author
-
Lupu, Lior, Banai, Ariel, Szekely, Yishay, Lichter, Yael, Hochstadt, Aviram, Taieb, Philippe, Sapir, Orly, Granot, Yoav, Merdler, Ilan, Ghantous, Eihab, Borohovitz, Ariel, Sadon, Sapir, Levi, Erez, Laufer-Perl, Michal, Banai, Shmuel, and Topilsky, Yan
- Subjects
- *
COVID-19 , *ECHOCARDIOGRAPHY , *COVID-19 treatment , *CORONAVIRUS diseases - Abstract
Recently, several therapeutic agents have decreased the progression to critical disease in patients with mild/moderate COVID-19. However, their use is limited to patients with ≥1 clinical risk factor. We aimed to evaluate echocardiographic features that may aid in risk stratification for patients with mild/moderate COVID-19. 278 consecutive patients with mild/moderate COVID-19 underwent prospective clinical and echocardiographic examination, ≤7 days of symptoms, as part of a predefined protocol. Analysis to identify echocardiographic predictors of outcome was performed. In the multivariable risk model, E/e′, TAPSE, and pulmonary acceleration time (PAT) were associated with the composite outcome (p = 0.01, 0.005, 0.05, respectively). Stepwise analyses showed that the addition of echocardiography on top of having ≥1 clinical risk factor and even using each parameter separately improved the prediction of outcomes. If patients were re-categorized as high risk only if having both ≥1 clinical and ≥ 1 echocardiography risk parameter (E/e′ > 8, TAPSE<1.8 cm, PAT<90 msec), or even one echo parameter separately, then specificity, positive predictive value, and accuracy improved. If patients were re-classified as high risk if having either ≥1 clinical risk factor or ≥ 1 high-risk echocardiography parameter, all five individuals who were missed by the ≥1 risk factor "rule", were correctly diagnosed as high risk. Similar analyses, including only patients with mild disease, showed that the addition of TAPSE improved the prediction of outcomes. In patients with mild/moderate COVID-19, a very limited echocardiographic exam is sufficient for improved outcome prediction, and may improve resource allocation for new anti-COVID-19 agents. We show that among patients with mild/moderate COVID-19, several easily obtained echocardiographic findings are strongly correlated with mortality or progression to the need for invasive/non-invasive mechanical ventilation, even when adjusted for the presence or absence of ≥1 clinical risk factor. Furthermore, even a limited echocardiographic exam is sufficient to develop a strategy of risk stratification. We believe that our data have important implications for the clinicians involved in the acute treatment of patients with COVID-19. • Among patients with mild/moderate COVID-19, several echocardiographic parameters are associated with clinical deteriorationicient to develop a strategy of risk stratification and improve outcome prediction • We show that E/e′, PAT, and TAPSE have additive predictive value on top of clinical risk factors • A limited echocardiographic exam is sufficient to develop a strategy of risk stratification and improve outcome prediction • In patients presenting with mild COVID-19, TAPSE has additive predictive value on top of clinical risk factors [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Relation of Gender to the Occurrence of AKI in STEMI Patients.
- Author
-
Frydman, Shir, Freund, Ophir, Banai, Ariel, Zornitzki, Lior, Banai, Shmuel, and Shacham, Yacov
- Subjects
- *
ST elevation myocardial infarction , *PERCUTANEOUS coronary intervention , *GENDER , *ACUTE kidney failure , *CHRONIC kidney failure - Abstract
Patients undergoing percutaneous coronary interventions (PCIs) are prone to a wide range of complications; one complication that is constantly correlated with a worse prognosis is acute kidney injury (AKI). Gender as an independent risk factor for said complications has raised some interest; however, studies have shown conflicting results so far. We aimed to investigate the possible relation of gender to the occurrence of AKI in STEMI patients undergoing PCI. This retrospective observational study cohort included 2967 consecutive patients admitted with STEMI between the years 2008 and 2019. Their renal outcomes were assessed according to KDIGO criteria (AKI serum creatinine ≥ 0.3 mg/dL from baseline within 48 h from admission), and in-hospital complications and mortality were reviewed. Our main results show that female patients were older (69 vs. 60, p < 0.001) and had higher rates of diabetes (29.2% vs. 23%, p < 0.001), hypertension (62.9% vs. 41.3%, p < 0.001), and chronic kidney disease (26.7% vs. 19.3%, p < 0.001). Females also had a higher rate of AKI (12.7% vs. 7.8%, p < 0.001), and among patients with AKI, severe AKI was also more prevalent in females (26.1% vs. 14.5%, p = 0.03). However, in multivariate analyses, after adjusting for the baseline characteristics above, the female gender was a non-significant predictor for AKI (adjusted OR 1.01, 95% CI 0.73–1.4, p = 0.94) or severe AKI (adjusted OR 1.65, 95% CI 0.80–1.65, p = 0.18). In conclusion, while females had higher rates of AKI and severe AKI, gender was not independently associated with AKI after adjusting for other confounding variables. Other comorbidities that are more prevalent in females can account for the difference in AKI between genders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Illness perceptions or recurrence risk perceptions: What comes first? A longitudinal cross-lagged examination among cardiac patients.
- Author
-
Peleg, Shira, Drori, Erga, Banai, Shmuel, Finkelstein, Ariel, and Shiloh, Shoshana
- Subjects
- *
DISEASE relapse , *CARDIAC patients , *LONGITUDINAL method , *MYOCARDIAL revascularization , *PSYCHOLOGY , *QUESTIONNAIRES , *SCALE analysis (Psychology) , *SELF-evaluation , *SELF-management (Psychology) , *STATISTICS , *TRANSLUMINAL angioplasty , *THEORY , *DATA analysis , *ACUTE coronary syndrome , *PATIENTS' attitudes , *DESCRIPTIVE statistics , *ATTITUDES toward illness - Abstract
Objectives:Previous research suggested that illness perceptions provide the basis for illness risk perceptions through an inductive reasoning process. This study aimed to assess the direction of relationships between illness and recurrence risk perceptions over time, among cardiac patients. Design:A longitudinal study was conducted among 138 patients undergoing coronary angioplasty. Self-report questionnaires measured perceived recurrence risk and illness perceptions one day and one month after catheterisation. Results:Cross-lagged Panel Model Analyses revealed that higher perceptions of timeline, consequences and emotional representations of illness at hospitalisation were associated with higher recurrence risk perceptions one month later. Perceived personal control was the only illness perception with bi-directional associations: higher perceived personal control at hospitalisation was associated with higher recurrence risk perceptions one month later; and higher recurrence risk perceptions at hospitalisation was associated with lower personal control one month later. Conclusions:The findings suggest that the associations between recurrence risk and illness perceptions can only partly be explained by inductive reasoning. Halo effects and defensive processes are suggested as complementary explanations for the observed associations between risk and illness perceptions. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
37. Sexual dysfunction, cardiovascular risk factors, and inflammatory biomarkers in women undergoing coronary angiography.
- Author
-
Oren, Amit, Megiddo, Elinor, Banai, Shmuel, and Justo, Dan
- Subjects
- *
CORONARY heart disease surgery , *BIOMARKERS , *C-reactive protein , *CARDIOVASCULAR diseases risk factors , *CHI-squared test , *COMPARATIVE studies , *CONFIDENCE intervals , *FIBRINOGEN , *FEMALE reproductive organ diseases , *INTERVIEWING , *LEUCOCYTES , *LONGITUDINAL method , *SCIENTIFIC observation , *PROBABILITY theory , *QUESTIONNAIRES , *REGRESSION analysis , *STATISTICAL sampling , *STATISTICAL hypothesis testing , *STATISTICS , *MATHEMATICAL variables , *SAMPLE size (Statistics) , *DATA analysis , *SEXUAL dysfunction , *DISEASE prevalence , *DATA analysis software , *DESCRIPTIVE statistics , *CORONARY angiography , *ODDS ratio , *KRUSKAL-Wallis Test - Abstract
We studied sexual dysfunction (SD) prevalence and lack of sexual activity in 117 women undergoing coronary angiography. SD was consistent with a low (≤26.55) Female Sexual Function Index questionnaire (FSFI) score. The mean age was 61.8 years (range: 40–75 years). SD prevalence was 76.1% (n = 89), and 41 (35.0%) women reported a lack of sexual activity. Regression analyses showed that only age was independently associated with SD (odds ratio 1.088; 95% confidence interval 1.024–1.157;p = .006) and lack of sexual activity (odds ratio 1.144; 95% confidence interval 1.064–1.230;p< .0001), regardless of cardiovascular risk factors, inflammatory biomarkers blood levels, and the number of stenotic coronary arteries. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
38. TCT-402 The Efficacy of Coronary Sinus Reducer in Patients With Refractory Angina Caused by Chronic Total Occlusion (CTO).
- Author
-
Konigstein, Maayan, Moroni, Alice, Verheye, Stefan, Freund, Ophir, Zornitzki, Lior, and Banai, Shmuel
- Subjects
- *
CHRONIC total occlusion , *ANGINA pectoris - Published
- 2024
- Full Text
- View/download PDF
39. BMI Modifies Increased Mortality Risk of Post-PCI STEMI Patients with AKI.
- Author
-
Schvartz, Reut, Lupu, Lior, Frydman, Shir, Banai, Shmuel, Shacham, Yacov, and Gal-Oz, Amir
- Subjects
- *
ST elevation myocardial infarction , *CORONARY care units , *CARDIAC intensive care , *ACUTE kidney failure , *LOGISTIC regression analysis - Abstract
Mortality from acute ST elevation myocardial infarction (STEMI) was significantly reduced with the introduction of percutaneous catheterization intervention (PCI) but remains high in patients who develop acute kidney injury (AKI). Previous studies found overweight to be protective from mortality in patients suffering from STEMI and AKI separately but not as they occur concurrently. This study aimed to establish the relationship between AKI and mortality in STEMI patients after PCI and whether body mass index (BMI) has a protective impact. Between January 2008 and June 2016, two thousand one hundred and forty-one patients with STEMI underwent PCI and were admitted to the Tel Aviv Medical Center Cardiac Intensive Care Unit. Their demographic, laboratory, and clinical data were collected and analyzed. We compared all-cause mortality in patients who developed AKI after PCI for STEMI and those who did not. In total, 178 patients (10%) developed AKI and had higher mortality (p < 0.001). Logistic regression analysis was performed to determine the relationship between AKI, BMI, and mortality. AKI was significantly associated with both 30-day and overall mortality, while BMI had a significant protective effect. Survival analysis found a significant difference in 30-day and overall survival between patients with and without AKI with a significant protective effect of BMI on survival at 30 days. AKI presents a major risk for mortality and poor survival after PCI for STEMI, yet a beneficial effect of increased BMI modifies it. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Biomarker-Guided Assessment of Acute Kidney Injury Phenotypes E among ST-Segment Elevation Myocardial Infarction Patients.
- Author
-
Banai, Ariel, Frydman, Shir, Abu Katash, Hytham, Stark, Moshe, Goldiner, Ilana, Banai, Shmuel, and Shacham, Yacov
- Subjects
- *
ST elevation myocardial infarction , *ACUTE kidney failure , *PHENOTYPES , *LIPOCALIN-2 - Abstract
Recent practice guidelines recommended the use of new stress, functional, and damage biomarkers in clinical practice to prevent and manage acute kidney injury (AKI). Biomarkers are one of the tools used to define various AKI phenotypes and provide prognostic information regardless of an acute decline in renal function. We investigated the incidence and possible implications of AKI phenotypes among ST elevation myocardial infarction patient treated with primary coronary intervention. We included 281 patients with STEMI treated with PCI. Neutrophil gelatinase associated lipocalin (NGAL) was utilized to determine structural renal damage and functional AKI was determined using the KDIGO criteria. Patients were stratified into four AKI phenotypes: no AKI, subclinical AKI, hemodynamic AKI, and severe AKI. Patients were assessed for in-hospital adverse events (MACE). A total of 46 patients (44%) had subclinical AKI, 17 (16%) had hemodynamic AKI, and 42 (40%) had severe AKI. We observed a gradual and significant increase in the occurrence of MACE between the groups being highest among patients with severe AKI (10% vs. 19% vs. 29% vs. 43%; p < 0.001). In a multivariable regression model, any AKI phenotype was independently associated with MACE with an odds ratio of 4.15 (95% CI 2.1–8.3, p < 0.001,) for subclinical AKI, 4.51 (95% CI 1.61–12.69; p = 0.004) for hemodynamic AKI, and 12.9 (95% CI 5.59–30.1, p < 0.001) for severe AKI. In conclusion, among STEMI patients, AKI is a heterogeneous condition consisting of distinct phenotypes, addition of novel biomarkers may overcome the limitations of sCr-based AKI definitions to improve AKI phenotyping and direct potential therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Outcomes of Patients Undergoing PCI of Ostial Coronary Lesions: A Single-Center Study.
- Author
-
Zornitzki, Lior, Hochstadt, Aviram, Loewenstein, Itamar, Erez, Johnathan, Wenkert, Atalia, Moshkovits, Yonatan, Toledano, Ella, Chorin, Ehud, Ben-Shoshan, Jeremy, Halkin, Amir, Bazan, Samuel, Arbel, Yaron, Finkelstein, Ariel, Banai, Shmuel, and Konigstein, Maayan
- Subjects
- *
DRUG-eluting stents , *PERCUTANEOUS coronary intervention , *MAJOR adverse cardiovascular events , *MUCOCUTANEOUS lymph node syndrome - Abstract
Introduction: Ostial coronary lesions are a subset of proximal coronary lesions, which are relatively more difficult to treat and were associated with worse clinical outcomes in the early percutaneous coronary intervention (PCI) era. Data regarding the outcomes of ostial lesions' PCI in the contemporary era are lacking. Methods: We conducted a single-center, all-comer, prospective registry study, enrolling patients undergoing PCI with the use of contemporary drug-eluting stents (DES) between July 2016 and February 2018. Included in the present analysis were only patients treated for proximal lesions. Clinical outcomes were compared between patients undergoing PCI of ostial versus proximal nonostial lesions. The primary endpoint was target vessel revascularization (TVR). Secondary endpoints included target lesion revascularization (TLR) and major cardiovascular adverse events (MACE) at 12 months. Results: A total of 334 (84.7% male, 67.3 ± 10.7 years) patients were included, of which 91 patients were treated for ostial lesions and 243 were treated for proximal nonostial lesions. Baseline and procedural characteristics were similar between the two groups. At 12 months, TVR and TLR were numerically higher among patients undergoing PCI of ostial versus nonostial lesions without reaching statistical significance (5.5% vs. 3.3%; p = 0.35 and 4.4% vs. 2.5%; p = 0.47, respectively). The rate of MACE was similar between the two groups. Conclusion: In patients undergoing PCI with the use of contemporary DES, clinical outcomes were similar among patients treated for ostial compared to proximal nonostial lesions. Larger studies are required to further evaluate the performance of contemporary DES in this subset of lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditis—Same or Different?
- Author
-
Zornitzki, Lior, Havakuk, Ofer, Rozenbaum, Zach, Viskin, Dana, Arbel, Yaron, Flint, Nir, Arnold, Joshua, Waissengein, Barliz, Wolf, Ido, Banai, Shmuel, Topilsky, Yan, and Laufer-Perl, Michal
- Abstract
Immune checkpoint inhibitor (ICI) and coronavirus disease 2019 (COVID-19) vaccine-induced myocarditis possibly share common mechanisms secondary to overactivation of the immune system. We aimed to compare the presenting characteristics of ICIs and COVID-19 vaccine-induced myocarditis. We performed a retrospective analysis of characteristics of patients diagnosed with either ICIs or COVID-19 vaccine-induced myocarditis and compared the results to a control group of patients diagnosed with acute viral myocarditis. Eighteen patients diagnosed with ICIs (ICI group) or COVID-19 vaccine (COVID-19 vaccine group)-induced myocarditis, and 20 patients with acute viral myocarditis (Viral group) were included. The ICI group presented mainly with dyspnea vs. chest pain and fever among the COVID-19 vaccine and Viral groups. Peak median high sensitivity Troponin I was markedly lower in the ICI group (median 619 vs. 15,527 and 7388 ng/L, p = 0.004). While the median left ventricular (LV) ejection fraction was 60% among all groups, the ICI group had a lower absolute mean LV global longitudinal strain (13%) and left atrial conduit strain (17%), compared to the COVID-19 vaccine (17% and 30%) and Viral groups (18% and 37%), p = 0.016 and p = 0.001, respectively. Despite a probable similar mechanism, ICI-induced myocarditis's presenting characteristics differed from COVID-19 vaccine-induced myocarditis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Temporal Trends of Transcatheter Aortic Valve Implantation over 12 Years: A High-Volume Single-Center Experience.
- Author
-
Frydman, Shir, Zahler, David, Merdler, Ilan, Freund, Ophir, Shacham, Yacov, Banai, Shmuel, Finkelstein, Ariel, and Steinvil, Arie
- Subjects
- *
HEART valve prosthesis implantation , *CARDIAC pacemakers , *DEATH rate - Abstract
Transcatheter aortic valve replacement (TAVR) has become the mainstay of treatment for patients with severe AS. Since the TAVR population and patients' outcomes have dramatically changed over the last decade, updated data regarding contemporary practice and trends are pertinent to clinical use. We performed a retrospective observational analysis of consecutive patient who underwent TAVR for symptomatic severe AS between the years 2009 and 2021 in a single high-volume center. Patients were divided into four equal time groups based on the procedure date (2009–2012, 2013–2015, 2016–2018 and 2019–2021). A total of 1988 patients were included in this study and divided into four groups, with 321, 482, 565 and 620 patients in groups 1–4, respectively. Significant trends were seen in baseline characteristics of a few parameters, including lower age, lower procedural risk and reduced rates of comorbidity (p for trend < 0.0001 for all factors mentioned above). A shift was seen in the procedural technique with lower balloon pre-dilatation and higher device success rates (p for trend < 0.0001). The post-procedural period changed over the years with fewer pacemaker placements (p < 0.0001) and reduced rates of AKI and post-procedural bleed (p value 0.02 and <0.0001, respectively). Furthermore, overall hospital stay was shortened from 7 ± 7.1 days to 2.3 ± 1.7 (p < 0.0001). Finally, patient follow up revealed reduced mortality rates at 30 days (p < 0.0001) and 1 year (p = 0.013). Multivariate regression revealed that a late implantation date was an independent protector from mortality (HR 0.84, p = 0.002). In conclusion, our study demonstrated that TAVR has become a safer practice over the years with reduced rates of morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Artificial Intelligence-Based Stethoscope for the Diagnosis of Aortic Stenosis.
- Author
-
Ghanayim, Tamer, Lupu, Lior, Naveh, Sivan, Bachner-Hinenzon, Noa, Adler, Doron, Adawi, Salim, Banai, Shmuel, and Shiran, Avinoam
- Subjects
- *
AORTIC stenosis , *STETHOSCOPES , *HEART murmurs , *HEART valve diseases , *HEART disease diagnosis , *DIAGNOSIS , *ECHOCARDIOGRAPHY , *ARTIFICIAL intelligence , *ALGORITHMS - Abstract
Background: The diagnostic accuracy of the stethoscope is limited and highly dependent on clinical expertise. Our purpose was to develop an electronic stethoscope, based on artificial intelligence (AI) and infrasound, for the diagnosis of aortic stenosis (AS).Methods: We used an electronic stethoscope (VoqX; Sanolla, Nesher, Israel) with subsonic capabilities and acoustic range of 3-2000 Hz. The study had 2 stages. In the first stage, using the VoqX, we recorded heart sounds from 100 patients referred for echocardiography (derivation group), 50 with moderate or severe AS and 50 without valvular disease. An AI-based supervised learning model was applied to the auscultation data from the first 100 patients used for training, to construct a diagnostic algorithm that was then tested on a validation group (50 other patients, 25 with AS and 25 without AS). In the second stage, conducted at a different medical center, we tested the device on 106 additional patients referred for echocardiography, which included patients with other valvular diseases.Results: Using data collected at the aortic and pulmonic auscultation points from the derivation group, the AI-based algorithm identified moderate or severe AS with 86% sensitivity and 100% specificity. When applied to the validation group, the sensitivity was 84% and specificity 92%; and in the additional testing group, 90% and 84%, respectively. The sensitivity was 55% for mild, 76% for moderate, and 93% for severe AS.Conclusion: Our initial findings show that an AI-based stethoscope with infrasound capabilities can accurately diagnose AS. AI-based electronic auscultation is a promising new tool for automatic screening and diagnosis of valvular heart disease. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
45. Valvular Heart Disease following Anthracycline Therapy—Is It Time to Look beyond Ejection Fraction?
- Author
-
Zahler, David, Arnold, Joshua H., Bar-On, Tali, Raphael, Ari, Khoury, Shafik, Rozenbaum, Zach, Banai, Shmuel, Arbel, Yaron, Topilsky, Yan, and Laufer-Perl, Michal
- Subjects
- *
HEART valve diseases , *VENTRICULAR ejection fraction , *MITRAL valve insufficiency , *HEART valves - Abstract
The association between anthracycline (ANT) and left ventricle (LV) dysfunction is well known; however, data regarding its direct effect on cardiac valve function is limited. We aimed to evaluate how ANT therapy affected valvular function in patients diagnosed with breast cancer. Data were prospectively collected as part of the Israel Cardio-Oncology Registry (ICOR). Patients underwent echocardiography exams at baseline (T1), during ANT therapy (T2), and after completion within 3 months (T3) and 6 months (T4). A total of 141 female patients were included, with a mean age of 51 ± 12 years. From T1 to T4, we observed a significant deterioration in LV ejection fraction (60.2 ± 1.5 to 59.2 ± 2.7%, p = 0.0004) and LV global longitudinal strain (−21.6 (−20.0–−23.0) to −20.0 (−19.1–−21.1)%, p < 0.0001)), and an increase in LV end-systolic diameter (25 (22–27) to 27 (24–30) mm, p < 0.0001). We observed a significant increase in the incidence of new mitral regurgitation (MR) development (4 to 19%, p < 0.0001), worsening with concomitant trastuzumab therapy (6% to 31%, p = 0.003), and a trend for tricuspid regurgitation development (4% to 8%, p = 0.19). ANT therapy is associated with the development of a new valvular disease, mainly MR, which may imply the need for a valvular focus in the monitoring of cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Echo Doppler Estimation of Pulmonary Capillary Wedge Pressure in Patients with Severe Aortic Stenosis.
- Author
-
Biner, Simon, Topilsky, Yan, Banai, Shmuel, Steinvil, Arie, Arbel, Yaron, Siegel, Robert James, Beigel, Roy, Keren, Gad, and Finkelstein, Ariel
- Subjects
- *
HEART failure , *AORTIC stenosis , *BLOOD pressure , *CARDIAC catheterization , *CARDIAC output , *STATISTICAL correlation , *DOPPLER echocardiography , *HEART beat , *PROSTHETIC heart valves , *LONGITUDINAL method , *SCIENTIFIC observation , *PULMONARY artery , *MULTIPLE regression analysis , *CONTINUING education units , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *DIAGNOSIS - Abstract
Background Transcatheter aortic valve replacement ( TAVR) has become a treatment option for patients with severe aortic stenosis ( AS) and high surgical risk. Assessment of symptoms in these patients is challenging because of advanced age, comorbidities, and limited physical activity. Noninvasive quantification of pulmonary capillary wedge pressure ( PCWP) in candidates for TAVR may be helpful for risk stratification. The objective of the study was to create a model for estimation of PCWP by echo Doppler in patients with severe AS. Methods and Results Data from 80 patients with severe AS referred for TAVR were used to develop an echo Doppler model for predicting PCWP. Its performance was evaluated in the test cohort of 33 patients who had invasive and noninvasive evaluation. No single echo Doppler parameter estimated PCWP accurately. In the retrospective analysis, the multilinear regression provided an accurate estimate of PCWP (r2 = 0.74). The model included, in order of importance (all P < 0.05), the ratio of early transmitral velocity (E) to annular velocity (E'), the left ventricular ejection fraction, and the velocity time integral of tricuspid regurgitation signal. In the prospective cohort of patients with severe AS, the model demonstrated good predictive ability of PCWP (r = 0.77, P < 0.01). Conclusion In patients with severe AS, noninvasive estimation of PCWP is possible by integration of two-dimensional, spectral, and tissue Doppler variables. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. Early Detection of Inflammation-Prone STEMI Patients Using the CRP Troponin Test (CTT).
- Author
-
Brzezinski, Rafael Y., Melloul, Ariel, Berliner, Shlomo, Goldiner, Ilana, Stark, Moshe, Rogowski, Ori, Banai, Shmuel, Shenhar-Tsarfaty, Shani, and Shacham, Yacov
- Subjects
- *
TROPONIN , *ST elevation myocardial infarction , *C-reactive protein , *ACUTE coronary syndrome , *MORTALITY - Abstract
Elevated concentrations of C-reactive protein (CRP) early during an acute coronary syndrome (ACS) may reflect the magnitude of the inflammatory response to myocardial damage and are associated with worse outcome. However, the routine measurement of both CRP and cardiac troponin simultaneously in the setting of ST-segment myocardial infarction (STEMI) is not used broadly. Here, we sought to identify and characterize individuals who are prone to an elevated inflammatory response following STEMI by using a combined CRP and troponin test (CTT) and determine their short- and long-term outcome. We retrospectively examined 1186 patients with the diagnosis of acute STEMI, who had at least two successive measurements of combined CRP and cardiac troponin (up to 6 h apart), all within the first 48 h of admission. We used Chi-Square Automatic Interaction Detector (CHAID) tree analysis to determine which parameters, timing (baseline vs. serial measurements), and cut-offs should be used to predict mortality. Patients with high CRP concentrations (above 90th percentile, >33 mg/L) had higher 30 day and all-cause mortality rates compared to the rest of the cohort, regardless of their troponin test status (above or below 118,000 ng/L); 14.4% vs. 2.7%, p < 0.01. Furthermore, patients with both high CRP and high troponin levels on their second measurement had the highest 30-day mortality rates compared to the rest of the cohort; 21.4% vs. 3.7%, p < 0.01. These patients also had the highest all-cause mortality rates after a median follow-up of 4.5 years compared to the rest of the cohort; 42.9% vs. 12.7%, p < 0.01. In conclusion, serial measurements of both CRP and cardiac troponin might detect patients at increased risk for short-and long-term mortality following STEMI. We suggest the future use of the combined CTT as a potential early marker for inflammatory-prone patients with worse outcomes following ACS. This sub-type of patients might benefit from early anti-inflammatory therapy such as colchicine and anti-interleukin-1ß agents. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. HEART FAILURE AS A PRESENTING SYMPTOM OF LYMPHOMA.
- Author
-
Ghantous, Eihab, Hochstadt, Aviram, Banai, Shmuel, Topilsky, Yan, and Perl, Michal Laufer
- Subjects
- *
LYMPHOMAS , *SYMPTOMS , *HEART failure - Published
- 2022
- Full Text
- View/download PDF
49. Smoking and Respiratory Diseases in Patients with Coronary Microvascular Dysfunction.
- Author
-
Freund, Ophir, Shetrit, Aviel, Bar-Shai, Amir, Zornitzki, Lior, Frydman, Shir, Banai, Ariel, Shamir, Reut Amar, Ben-Shoshan, Jeremy, Arbel, Yaron, Banai, Shmuel, and Konigstein, Maayan
- Subjects
- *
RESPIRATORY diseases , *MICROCIRCULATION disorders , *CORONARY disease , *CHRONIC obstructive pulmonary disease , *RETENTION of urine , *CORONARY artery disease - Abstract
Coronary microvascular disease (CMD) is common in patients with and without obstructive coronary artery disease, and is associated with adverse clinical outcomes. Respiratory-related variables are associated with pulmonary and systemic microvascular dysfunction, while evidence about their relationship with CMD is limited. We aim to evaluate respiratory-related variables as risk factors of CMD. This is an observational, single-center study enrolling consecutive patients undergoing invasive evaluation of coronary microvascular function in the catheterization laboratory. Patients with evidence of obstructive coronary artery disease or with missing data were excluded. Associations between respiratory-related variables and indices of CMD were assessed using univariate and multivariate regression models. Overall, 266 patients (mean age 67 ± 11 years, 59% females) were included in the current analysis. Of those, 155 (58%) had evidence of CMD. Among the respiratory variables, independent predictors of CMD were current smoking (adjusted odds ratio [AOR] 2.5; 95% confidence interval [CI], 1.2-5; P =.01) and obstructive sleep apnea (AOR 5.7; 95% CI, 1.2-26; P =.03), while chronic obstructive pulmonary disease was not. Among ever-smokers, higher smoking pack-years was an independent risk factor for CMD (median 35 vs 25 pack-years, AOR 1.09; 95% CI, 1.04-1.13; P <.01), and was associated with higher rates of pathologic index of microcirculatory resistance and resistive reserve ratio. In patients undergoing invasive coronary microvascular evaluation, current smoking and obstructive sleep apnea are independently associated with CMD. Among smokers, higher pack-years is a strong predictor for CMD. Our findings should raise awareness for prevention and possible treatment options. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Predictive Value of Elevated Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels for Assessment of Cardio–Renal Interactions among ST-Segment Elevation Myocardial Infarction Patients.
- Author
-
Zahler, David, Merdler, Ilan, Banai, Ariel, Shusterman, Eden, Feder, Omri, Itach, Tamar, Robb, Leemor, Banai, Shmuel, and Shacham, Yacov
- Subjects
- *
ST elevation myocardial infarction , *LIPOCALIN-2 , *MYOCARDIAL infarction , *MAJOR adverse cardiovascular events , *ACUTE kidney failure , *VENTRICULAR ejection fraction - Abstract
Background: Elevated serum neutrophil gelatinase-associated lipocalin (NGAL) levels reflect both inflammatory reactions and renal tubular injury. Recently, associations with endothelial dysfunction and plaque instability were also proposed. We investigated the prognostic utility of elevated NGAL levels for renal and clinical outcomes among ST-segment elevation myocardial infarction (STEMI) patients treated with primary coronary intervention (PCI). Methods: We performed a prospective, observational, open-label trial. High NGAL was defined as values within the third tertile (>66 percentile). Results: A total of 267 patients were included (mean age 66 ± 14 years, 81% males). Short-term adverse outcomes were consistently increased in the high NGAL group with more acute kidney injury, lower mean left ventricular ejection fraction, higher 30-day mortality, and higher incidence for the composite outcome of major adverse cardiac events (MACE). In a multivariate logistic regression model, high NGAL emerged as a strong and independent predictor for MACE (OR 2.07, 95% CI 1.15–3.73, p = 0.014). Conclusions: Among STEMI patients undergoing primary PCI, elevated NGAL levels are associated with adverse renal and cardiovascular outcomes, independent of traditional inflammatory markers. Further studies are needed to assess the potentially unique role of NGAL in cardio–renal interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.